Home › Funds › Catalio Capital Management, LP › MGX

Catalio Capital Management, LP position in MGX

METAGENOMI THERAPEUTICS INC · Health Care

Catalio Capital Management, LP reported holding 528,993 shares of MGX (METAGENOMI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$630K, representing 0.12% of its reported portfolio and ranking #37 among its reported holdings. Catalio Capital Management, LP has disclosed MGX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)528.99K sh
Reported value held$629.50K
Portfolio Weight0.12%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's MGX position evolved

Catalio Capital Management, LP first disclosed a stake in MGX in Q4 2024 at 528,993 shares (US$1.9M). Across 7 filings, Catalio Capital Management, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 528,993 shares valued at US$630K.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 528.99K $1.91M New
Q1 2025 528.99K $719.43K Hold
Q2 2025 528.99K $782.91K Hold
Q3 2025 528.99K $1.25M Hold
Q4 2025 528.99K $856.97K Hold
Q1 2026 528.99K $708.85K Hold
Q2 2026 528.99K $629.50K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MGX and 13F data

MGX (METAGENOMI THERAPEUTICS INC) is a Health Care company. 23 other funds we track also report a position in MGX — the largest reported positions include PURA VIDA INVESTMENTS, LLC (US$315K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MGX

All MGX fund holders →

FAQ

How long has Catalio Capital Management, LP held MGX?

Catalio Capital Management, LP has disclosed MGX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Catalio Capital Management, LP's current position in MGX?

As of Q2 2026, Catalio Capital Management, LP holds 528.99K shares of MGX (METAGENOMI THERAPEUTICS INC), valued at $629.50K, representing 0.12% of its reported portfolio and ranking #37.

Has Catalio Capital Management, LP been buying or selling MGX?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP held unchanged its position in MGX.

Which other funds hold MGX?

Other major institutional holders of MGX include PURA VIDA INVESTMENTS, LLC, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.